Patent foramen ovale and cerebrovascular diseases

Nature Clinical Practice Cardiovascular Medicine

Volumn 3, Issue 8, 2006, Pages 446-455

  Desai, Amish J ^a   Fuller, Cindy J ^a   Jesurum, Jill T ^a   Reisman, Mark ^a  

^a SWEDISH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BLOOD CLOTTING FACTOR 5 LEIDEN; CLOPIDOGREL; PROTHROMBIN; WARFARIN;

AGING; CARDIOPULMONARY BYPASS; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; CLIP; DEEP VEIN THROMBOSIS; DISEASE PREDISPOSITION; DISEASE SEVERITY; DOPPLER ECHOGRAPHY; FOLLOW UP; GENE MUTATION; HEART ATRIUM SEPTUM DEFECT; HEART TAMPONADE; HEART VENTRICLE FIBRILLATION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INCIDENCE; INTERMETHOD COMPARISON; INTERNATIONAL NORMALIZED RATIO; MEDLINE; MIGRAINE; MINIMALLY INVASIVE CARDIAC SURGERY; PARADOXICAL EMBOLISM; PATHOPHYSIOLOGY; PERIOPERATIVE PERIOD; POSTOPERATIVE COMPLICATION; PREVALENCE; PRIORITY JOURNAL; RECURRENCE RISK; RECURRENT DISEASE; REOPERATION; REVIEW; RISK ASSESSMENT; RISK FACTOR; STROKE; SURGICAL EQUIPMENT; SURGICAL TECHNIQUE; SYMPTOM; SYSTEMATIC REVIEW; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; TRANSTHORACIC ECHOCARDIOGRAPHY; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR CIRCULATION; CEREBROVASCULAR DISORDERS; CLINICAL TRIALS; CLINICAL TRIALS AS TOPIC; HEART SEPTAL DEFECTS, ATRIAL; HUMANS; INTRACRANIAL EMBOLISM; MIGRAINE DISORDERS; RISK FACTORS; STROKE; UNITED STATES;

EID: 33746628913     PISSN: 17434297     EISSN: 17434300     Source Type: Journal    
DOI: 10.1038/ncpcardio0597     Document Type: Review

References (66)

1. American Heart Association (online 11 January 2006) Heart Disease and Stroke Statistics-2006 Update [http://www.americanheart.org/ presenter.jhtml?identifier=1928] (accessed 20 April 2006)
2. Sacco RL et al. (1989) Infarcts of undetermined cause: The NINCDS Stroke Data Bank. Ann Neurol 25: 382-390
3. Hagen PT et al. (1984) Incidence and size of patent foramen ovale during the first 10 decades of life: An autopsy study of 965 normal hearts. Mayo Clin Proc 59: 17-20
4. Meier B and Lock JE (2003) Contemporary management of patent foramen ovale. Circulation 107: 5-9
5. Klötzsch C et al. (1996) An increased frequency of patent foramen ovale in patients with transient global amnesia: Analysis of 53 consecutive patients. Arch Neurol 53: 504-508
6. Webster MW et al. (1988) Patent foramen ovale in young stroke patients. Lancet 2: 11-12
7. Lechat P et al. (1988) Prevalence of patent foramen ovale in patients with stroke. N Engl J Med 318: 1148-1152
8. Cabanes L et al. (1993) Atrial septal aneurysm and patent foramen ovale as risk factors for cryptogenic stroke in patients less than 55 years of age. A study using transesophageal echocardiography. Stroke 24: 1865-1873
9. Overell JR et al. (2000) Interatrial septal abnormalities and stroke: A meta-analysis of case-control studies. Neurology 55: 1172-1179
10. Kerut EK et al. (2001) Patent foramen ovale: A review of associated conditions and the impact of physiological size. J Am Coll Cardiol 38: 613-623
11. Wilmshurst PT et al. (2004) Inheritance of persistent foramen ovale and atrial septal defects and the relation to familial migraine with aura. Heart 90: 1315-1320
12. Meissner I et al. (1999) Prevalence of potential risk factors for stroke assessed by transesophageal echocardiography and carotid ultrasonography: The SPARC study. Stroke Prevention: Assessment of Risk in a Community. Mayo Clin Proc 74: 862-869
13. Hamann GF et al. (1998) Femoral injection of echo contrast medium may increase the sensitivity of testing for a patent foramen ovale. Neurology 50: 1423-1428
14. Spencer MP et al. (2004) Power m-mode transcranial Doppler for diagnosis of patent foramen ovale and assessing transcatheter closure. J Neuroimaging 14: 342-349
15. Serena J et al. (1998) The need to quantify right-to-left shunt in acute ischemic stroke: A case-control study. Stroke 29: 1322-1328
16. Jauss M et al. (2000) Detection of right-to-left shunt with ultrasound contrast agent and transcranial Doppler sonography. Cerebrovasc Dis 10: 490-496
17. Di Tullio M et al. (1993) Comparison of diagnostic techniques for the detection of a patent foramen ovale in stroke patients. Stroke 24: 1020-1024
18. Arquizan C et al. (2001) Is patent foramen ovale a family trait? A transcranial Doppler sonographic study. Stroke 32: 1563-1566
19. Wilmshurst PT et al. (2000) Effect on migraine of closure of cardiac right-to-left shunts to prevent recurrence of decompression illness or stroke or for haemodynamic reasons. Lancet 356: 1648-1651
20. Falk V et al. (1997) Trapped thrombus in a patent foramen ovale. Thorac Cardiovasc Surg 45: 90-92
21. Berthet K et al. (2000) Significant association of atrial vulnerability with atrial septal abnormalities in young patients with ischemic stroke of unknown cause. Stroke 31: 398-403
22. Steiner MM et al. (1998) Patent foramen ovale size and embolic brain imaging findings among patients with ischemic stroke. Stroke 29: 944-948
23. De Castro S et al. (2000) Morphological and functional characteristics of patent foramen ovale and their embolic implications. Stroke 31: 2407-2413
24. Homma S et al. (2002) Effect of medical treatment in stroke patients with patent foramen ovale: Patent Foramen Ovale in Cryptogenic Stroke Study. Circulation 105: 2625-2631
25. Anzola GP et al. (2003) Transcranial Doppler and risk of recurrence in patients with stroke and patent foramen ovale. Eur J Neurol 10: 129-135
26. Hanley PC et al. (1985) Diagnosis and classification of atrial septal aneurysm by two-dimensional echocardiography: Report of 80 consecutive cases. J Am Coll Cardiol 6: 1370-1382
27. Mas JL et al. (2001) Recurrent cerebrovascular events associated with patent foramen ovale, atrial septal aneurysm, or both. N Engl J Med 345: 1740-1746
28. Schuchlenz H et al. (2004) Persisting eustachian valve in adults: relation to patent foramen ovale and cerebrovascular events. J Am Soc Echocardiogr 17: 231-233
29. Ranoux D et al. (1993) Patent foramen ovale: Is stroke due to paradoxical embolism? Stroke 24: 31-34
30. Cramer SC et al. (2004) Increased pelvic vein thrombi in cryptogenic stroke: Results of the Paradoxical Emboli From Large Veins in Ischemic Stroke (PELVIS) Study. Stroke 35: 46-50
31. Pezzini A et al. (2003) Inherited thrombophilic disorders in young adults with ischemic stroke and patent foramen ovale. Stroke 34: 28-33
32. Karttunen V et al. (2003) Factor V Leiden and prothrombin gene mutation may predispose to paradoxical embolism in subjects with patent foramen ovale. Blood Coagul Fibrinolysis 14: 261-268
33. Lichy C et al. (2003) Prothrombin G20210A mutation, but not factor V Leiden, is a risk factor in patients with persistent foramen ovale and otherwise unexplained cerebral ischemia. Cerebrovasc Dis 16: 83-87
34. Bogousslavsky J et al. (1996) Stroke recurrence in patients with patent foramen ovale: The Lausanne Study. Lausanne Stroke with Paradoxal Embolism Study Group. Neurology 4: 1301-1305
35. Homma S et al. (2004) Age as a determinant of adverse events in medically treated cryptogenic stroke patients with patent foramen ovale. Stroke 35: 2145-2149
36. Homma S et al. (1997) Surgical closure of patent foramen ovale in cryptogenic stroke patients. Stroke 28: 2376-2381
37. Dearani JA et al. (1999) Surgical patent foramen ovale closure for prevention of paradoxical embolism-related cerebrovascular ischemic events. Circulation 100 (Suppl): II171-II175
38. Devuyst G et al. (1996) Prognosis after stroke followed by surgical closure of patent foramen ovale: A prospective follow-up study with brain MRI and simultaneous transesophageal and transcranial Doppler ultrasound. Neurology 47: 1162-1166
39. Landzberg MJ and Khairy P (2004) Indications for the closure of patent foramen ovale. Heart 90: 219-224
40. Hung J et al. (2000) Closure of patent foramen ovale for paradoxical emboli: Intermediate-term risk of recurrent neurological events following transcatheter device placement. J Am Coll Cardiol 35: 1311-1316
41. Wahl A et al. (2001) Prognosis after percutaneous closure of patent foramen ovale for paradoxical embolism. Neurology 57: 1330-1332
42. Bruch L et al. (2002) Transcatheter closure of interatrial communications for secondary prevention of paradoxical embolism: Single center experience. Circulation 105: 2845-2848
43. Onorato E et al. (2003) Patent foramen ovale with paradoxical embolism: mid-term results of transcatheter closure in 256 patients. J Interv Cardiol 16: 43-50
44. Hong TE et al. (2003) Transcatheter closure of patent foramen ovale associated with paradoxical embolism using the Amplatzer® PFO occluder: initial and intermediate-term results of the US multicenter clinical trial. Catheter Cardiovasc Interv 60: 524-528
45. Giardini A et al. (2004) Comparison of results of percutaneous closure of patent foramen ovale for paradoxical embolism in patients with versus without thrombophilia. Am J Cardiol 94: 1012-1016
46. De Ridder S et al. (2005) Percutaneous transcatheter closure of atrial septal defects: Initial single-centre experience and follow-up results. Initial experience with three-dimensional echocardiography. Acta Cardiol 60: 171-178
47. Chatterjee T et al. (2005) Interventional closure with Amplatzer® PFO occluder of patent foramen ovale in patients with paradoxical cerebral embolism. J Interv Cardiol 18: 173-179
48. Schuchlenz HW et al. (2005) Secondary prevention after cryptogenic cerebrovascular events in patients with patent foramen ovale. Int J Cardiol 101: 77-82
49. Sharifi M et al. (2005) Intense migraines secondary to percutaneous closure of atrial septal defects. J Interv Cardiol 18: 181-183
50. Krumsdorf U et al. (2004) Incidence and clinical course of thrombus formation on atrial septal defect and patent foramen ovale closure devices in 1,000 consecutive patients. J Am Coll Cardiol 43: 302-309
51. Khairy P et al. (2003) Transcatheter closure versus medical therapy of patent foramen ovale and presumed paradoxical thromboemboli: A systematic review. Ann Intern Med 139: 753-760
52. Lipton RB et al. (2002) Migraine in the United States: Epidemiology and patterns of health care use. Neurology 58: 885-894
53. Del Sette M et al. (1998) Migraine with aura and right-to-left shunt on transcranial Doppler: A case-control study. Cerebrovasc Dis 8: 327-330
54. Schwerzmann M et al. (2005) Prevalence and size of directly detected patent foramen ovale in migraine with aura. Neurology 65: 1415-1418
55. Kurth T et al. (2005) Migraine, headache, and the risk of stroke in women: A prospective study. Neurology 64: 1020-1026
56. Lamy C et al. (2002) Clinical and imaging findings in cryptogenic stroke patients with and without patent foramen ovale: The PFO-ASA Study. Atrial Septal Aneurysm. Stroke 33: 706-711
57. Milhaud D et al. (2001) Ischemic stroke and active migraine. Neurology 57: 1805-1811
58. Kruit MC et al. (2004) Migraine as a risk factor for subclinical brain lesions. JAMA 291: 427-434
59. Buring JE et al. (1995) Migraine and subsequent risk of stroke in the Physicians' Health Study. Arch Neurol 52: 129-134
60. Etminan M et al. (2005) Risk of ischaemic stroke in people with migraine: Systematic review and meta-analysis of observational studies. BMJ 330: 63-64
61. Reisman M et al. (2005) Migraine headache relief after transcatheter closure of patent foramen ovale. J Am Coll Cardiol 45: 493-495
62. Stone DA et al. (1996) Patent foramen ovale: Association between the degree of shunt by contrast transesophageal echocardiography and the risk of future ischemic neurologic events. Am Heart J 131: 158-161
63. Windecker S et al. (2004) Comparison of medical treatment with percutaneous closure of patent foramen ovale in patients with cryptogenic stroke. J Am Coll Cardiol 44: 750-758
64. Morandi E et al. (2003) Transcatheter closure of patent foramen ovale: A new migraine treatment? J Interv Cardiol 16: 39-42
65. Schwerzmann M et al. (2004) Percutaneous closure of patent foramen ovale reduces the frequency of migraine attacks. Neurology 62: 1399-1401
66. Azarbal B et al. (2005) Association of interatrial shunts and migraine headaches: Impact of transcatheter closure. J Am Coll Cardiol 45: 489-492